Metastatic Breast Carcinoma

  • John Hill
  • G. Thomas Budd
Part of the Current Clinical Oncology book series (CCO)


Carcinoma of the breast is the most frequent cancer in women in the United States and the second leading cause of cancer deaths. In the year 2005, it is estimated that more than 210,000 new cases will be diagnosed, while approx 40,000 will die from the disease. A slight decrease in mortality has been noted in recent years, attributable to improved screening practices as well as modest improvements in treatment (1).


Breast Cancer Vertebral Fracture Clin Oncol Metastatic Breast Cancer Aromatase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, Thomas A, Murray T, Ward E, et al. Cancer statistics 2006. CA Cancer J Clin 2002;55:10–30.CrossRefGoogle Scholar
  2. 2.
    Dignam J. Differences in breast cancer prognosis among African-American and caucasian women. CA Cancer J Clin 2000; 50:50–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Saarto T, Blomqvist C, Virrkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19:10–17.PubMedGoogle Scholar
  4. 4.
    Brown H, Healey J. Metastatic Cancer to the Bone. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer Principles & Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:2713–2729.Google Scholar
  5. 5.
    Colleoni M, O’Neill A, Goldhirsch A, et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 2000; 18:3925–3935.PubMedGoogle Scholar
  6. 6.
    Domchek SM, Younger J, Finkelstein DM, Seiden MV. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 2000;89:363–368.PubMedCrossRefGoogle Scholar
  7. 7.
    Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998; 77:336–340.PubMedGoogle Scholar
  8. 8.
    Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999;79:1179–1181.PubMedCrossRefGoogle Scholar
  9. 9.
    The Breast Specialty Group of the British Association of Surgical Oncology. The management of metastatic bone disease in the United Kingdom. Eur J Surg Oncol 1999; 25:3–23.CrossRefGoogle Scholar
  10. 10.
    Frassica DA, Thurman S, Welsh J. Radiation therapy. Orthop Clin North Am 2000; 31:557–566.PubMedCrossRefGoogle Scholar
  11. 11.
    Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994; 30A:22–27.PubMedCrossRefGoogle Scholar
  12. 12.
    Heimdal K, Hirschberg H, Slettebo H, Watne K, Nome O. High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol 1992; 12:141–144.PubMedCrossRefGoogle Scholar
  13. 13.
    Diel IJ, Solomayer E, Costa S, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357–363.PubMedCrossRefGoogle Scholar
  14. 14.
    Theriault RL, Lipton A, Hortobagyi G, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999; 17:846–854.PubMedGoogle Scholar
  15. 15.
    Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guidelines on the role of bisphosphonates in breast cancer. J Clin Oncol 2000; 18:1378–1391.PubMedGoogle Scholar
  16. 16.
    Hortobagyi, GN. Treatment of breast cancer. N Engl J Med 1998; 339:974–984.PubMedCrossRefGoogle Scholar
  17. 17.
    Fossati R, Confalonieri C, Torri V, et al: Cytotoxic and hormonal treatment for metastatic breast cancer: a systemic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439–3460.PubMedGoogle Scholar
  18. 18.
    Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the clinical screening cooperative group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13:314–322.PubMedGoogle Scholar
  19. 19.
    Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999 17:485–493.PubMedGoogle Scholar
  20. 20.
    Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intra venous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737–744.PubMedGoogle Scholar
  21. 21.
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783–792.PubMedCrossRefGoogle Scholar
  22. 22.
    Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18:3748–3457.PubMedGoogle Scholar
  23. 23.
    Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19:2596–2606.PubMedGoogle Scholar
  24. 24.
    Buzdar AU, Jonat W, Howell A, et al. Anastrozole vs megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on the combined analysis of data from two mature phase III trials: Arimidex Study Group. Cancer 1998; 83:1142–1152.PubMedCrossRefGoogle Scholar
  25. 25.
    Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trail showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16:453–461.PubMedGoogle Scholar
  26. 26.
    Kaufmann M, Bajetta E, Dirix LY, et al. Exemstane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000; 18:1399–1411.PubMedGoogle Scholar
  27. 27.
    Wetzel FT, Phillips FM. Management of metastatic disease of the spine. Orthop Clin North Am 2000; 31:611–621.PubMedCrossRefGoogle Scholar
  28. 28.
    Galasko CSB. Spinal instability secondary to metastatic cancer. J Bone Joint Surg (Br) 1991; 73B:104–108.Google Scholar
  29. 29.
    Maranzano E, Latini P, Checcaglini F, et al. Radiation therapy in metastatic spinal cord compression: a prospective analysis of 105 consecutive patients. Cancer 1991; 67:1311–1317.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, Inc., Totowa, NJ 2006

Authors and Affiliations

  • John Hill
    • 1
  • G. Thomas Budd
    • 2
  1. 1.Mohamad Hussein Myeloma Research Program, Taussig Cancer CenterThe Cleveland Clinic FoundationCleveland
  2. 2.Hematology and Medical Oncology, Taussig Cancer CenterThe Cleveland Clinic FoundationCleveland

Personalised recommendations